Infectious Disease · AntiviralRegulatory Approvalregulatorymid-term

FDA Accepts Supplement for Aciclovir ANDA210401 by Yiling

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 7:00:41 AM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of Yiling's supplemental application for Aciclovir is a significant regulatory milestone that could strengthen Yiling's competitive position in the antiviral market. Pharma strategy teams should closely monitor this development as it may influence market dynamics and pricing strategies for Aciclovir and similar products. Regulatory context from FDA (FDA AP — ACYCLOVIR (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact on market share and pricing strategies for Aciclovir and similar antivirals. The strongest clinical anchor is Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoi (ClinicalTrials.gov), mechanism alignment (io ). In Infectious Disease · Antiviral, 7 regulatory and 2 competitive items passed relevance filtering for Yiling.

Competitive Pressure

The most relevant competitive pressure comes from Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector. This acceptance may enhance Yiling's position in the antiviral market, particularly for Aciclovir, which is a key treatment for herpes simplex virus.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ACYCLOVIR (SUPPL) (FDA). Entity match (yiling); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval will determine the actual impact on market availability and compliance.

Key Risks

Elevated medium regulatory exposure for Yiling could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If approved, Yiling could capture additional market share, potentially affecting pricing strategies and revenue for competitors in the antiviral space.
Upside for Yiling may improve if Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Yiling may improve if Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the potential impact on market share and pricing strategies for Aciclovir and similar antivirals.

What Would Change This Assessment

This becomes more urgent if Monitor the progress of the review and any subsequent approvals or market entries by competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Entity match (yiling); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACYCLOVIR (SUPPL)
FDAhigh relevance
Entity match (yiling); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Notice: Register of authorised online sellers of medicines in Northern Ireland
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoi
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Can Vitamin D Replacement Correct Chronic Disease Anemia?
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Probing Gut-Brain Communication in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Accepts Supplemental Application for TRYNGOLZA Autoinjector
Humanexa Signalsmedium relevance
Moderate corpus alignment

A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View source
Rarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Yiling
Aciclovir

Commercial impact

medium

If approved, Yiling could capture additional market share, potentially affecting pricing strategies and revenue for competitors in the antiviral space.

Regulatory impact

medium

The acceptance of the supplemental application indicates a positive regulatory trajectory, but the final approval will determine the actual impact on market availability and compliance.

What to watch

Monitor the progress of the review and any subsequent approvals or market entries by competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.